Phase 2Terminated

PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer (RELEASE)

A Multi-Center Randomised Open-Label Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy Versus Gemcitabine/Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma

Sponsor
PCI Biotech AS (Industry)
Enrollment
41 enrolled
Conditions
Cholangiocarcinoma
Interventions
Fimaporfin and Gemcitabine; Gemcitabine/Cisplatin chemotherapy
Ages
adults, older adults
Registry
NCT04099888

Full record on ClinicalTrials.gov

From the registry

This study will assess the safety and effectiveness of fimaporfin-induced photochemical internalisation (PCI) of gemcitabine complemented by systemic gemcitabine/cisplatin chemotherapy compared to gemcitabine/cisplatin alone, in patients with inoperable cholangiocarcinoma (CCA). Participants will be randomly assigned to one of the treatment groups and will receive study treatment for 6 months, followed by assessments every 3 months, as applicable.

Primary outcomes

  • Progression-free Survival (PFS)

History

  1. Results first posted

  2. Last registry update

  3. Study completion

  4. Primary completion

  5. Registered

  6. Started